Literature DB >> 20503893

Alloimmunization and clinical profile of sickle cell disease patients from Salvador-Brazil.

Angela Maria Dias Zanette1, Marilda de Souza Gonçalves, Laíse Vilasboas Schettini, Lais Magalhães Aguiar, Regina Célia Santos Bahia, Luciana Araujo Vasconcelos Nogueira, Cláudio José de Freitas Brandão, Ana Claudia Neves de Azevedo, Luciana Ramos de Aragao, Sérgio Marcos Arruda.   

Abstract

Sickle cell disease (SCD) is an important public health issue in Bahia, Brazil. Erythrocyte transfusions may reduce morbidity of SCD, however, they are associated with numerous risks. Among other risk categories, alloimmunization to red cell antigens may result from transfusions. The aim of this study was to compare the clinical profile of transfused adult SCD patients with and without alloantibodies. The study included 108 patients (105 homozygous SS and three with hemoglobinopathy SC), followed in the Outpatient Unit of the Hematology and Hemotherapy Center of Bahia. A retrospective review of clinical records of adult SCD patients who received at least three red blood cell transfusions from 2004 to 2007 was performed. Transfusion units were phenotypically matched for ABH-D and C,c,E,e, and K antigens. Alloimmunization developed in 56 patients (53 SS and three SC). The most prevalent alloantibodies were anti-E, anti-K, and anti-C (39.3%, 21.4%, and 16.1%, respectively). Age, sex and positive antiglobulin test displayed statistically significant differences. Prevalence of clinical complications such as leg ulcers, stroke, and others did not show differences between groups. In conclusion, alloimmunization did not significantly modify the clinical outcomes of SCD patients from Bahia, Brazil.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503893

Source DB:  PubMed          Journal:  Ethn Dis        ISSN: 1049-510X            Impact factor:   1.847


  6 in total

Review 1.  Optimized Antigen-Matched in Sickle Cell Disease Patients: Chances and Challenges in Molecular Times - the Brazilian Way.

Authors:  Lilian Castilho; Carla Luana Dinardo
Journal:  Transfus Med Hemother       Date:  2018-07-06       Impact factor: 3.747

2.  Evaluation of the New Lateral Flow Card MDmulticard® Basic Extended Phenotype in Routine Clinical Practice.

Authors:  Beate Mayer; Julia Müller; María-José Candela-García; Annie-Claude Manteau; Christof Weinstock; Axel Pruß
Journal:  Transfus Med Hemother       Date:  2018-03-09       Impact factor: 3.747

3.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

4.  Frequency of Red Blood Cell Alloimmunization in Patients with Sickle Cell Disease in Palestine.

Authors:  Fekri Samarah; Mahmoud A Srour; Dirgham Yaseen; Kamal Dumaidi
Journal:  Adv Hematol       Date:  2018-06-06

5.  Transfusion Practice, Post-Transfusion Complications and Risk Factors in Sickle Cell Disease in Senegal, West Africa.

Authors:  Moussa Seck; Alioune Badara Senghor; Mossane Loum; Sokhna Aissatou Touré; Blaise Félix Faye; Alioune Badara Diallo; Mohamed Keita; Seydi Elimane Bousso; Sérigne Mourtalla Guèye; Macoura Gadji; Abibatou Sall; Awa Oumar Touré; Saliou Diop
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-01-01       Impact factor: 2.576

6.  Clinical significance of antibody specificities to M, N and Lewis blood group system.

Authors:  Raj Nath Makroo; Bhavna Arora; Aakanksha Bhatia; Mohit Chowdhry; Rosamma Nakamatathil Luka
Journal:  Asian J Transfus Sci       Date:  2014-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.